Initiates Coverage on OncoCyte (NYSE:OCX) began coverage on shares of OncoCyte (NYSE:OCXGet Rating) in a report published on Wednesday morning. The brokerage issued a sell rating on the stock.

OncoCyte Price Performance

Shares of OCX stock opened at $0.39 on Wednesday. The company’s 50-day moving average price is $0.41. OncoCyte has a 12 month low of $0.24 and a 12 month high of $1.75. The firm has a market capitalization of $46.27 million, a price-to-earnings ratio of -0.60 and a beta of 1.73.

OncoCyte (NYSE:OCXGet Rating) last announced its quarterly earnings results on Thursday, November 10th. The company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.05. The firm had revenue of $1.02 million for the quarter, compared to analyst estimates of $1.50 million.

OncoCyte Company Profile

(Get Rating)

OncoCyte Corp. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. Its products include DetermaRx and DetermaIO. The firm also offers pharmaceutical services like multi-analyte test development and clinical trial services.

Recommended Stories

Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with's FREE daily email newsletter.